Cambridge spin-out XO1, which is developing anticoagulants that could have a sizeable impact on preventing heart attacks and strokes, has received $11m from Index Ventures.
The life science investor was the sole participant in the $11m round, made through Index’s $200m Life Sciences fund launched last year, and represents the company’s largest investment in a life science company to date.
The funding will be used to develop ichorcumab, an antibody created by researchers at the University of Cambridge and affiliated…
